Milton Park CRS
Welcome,         Profile    Billing    Logout  
 4 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mahachi, Rachel
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
12/24
11/25
Metcalfe, John
NCT04311502: Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Completed
2
104
RoW
Clofazimine (CFZ), Rifapentine (RPT), Isoniazid (INH), Pyrazinamide (PZA), Ethambutol (EMB), Rifampicin (RIF), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
06/24
06/24
TSELiOT, NCT05553236: Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis

Not yet recruiting
N/A
2500
RoW
Targeted next-generation sequencing
University of California, San Francisco, University of Stellenbosch, National Health Laboratory Service (NHLS), South Africa, National Institute for Communicable Diseases, South Africa, National Institute of Allergy and Infectious Diseases (NIAID), Find, Translational Genomics Research Institute, University Hospital Heidelberg
Drug-resistant Tuberculosis, HIV Coinfection, Cost-Benefit Analysis
01/27
01/27
Leader, CRS
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed
1
38
RoW
CH505TF gp120, GLA-SE adjuvant, Placebo
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
07/24
07/24
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Active, not recruiting
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25
Mukwekwerere, Pamela G
PALISADE, NCT06134362: Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Not yet recruiting
3
3500
RoW
CAB LA, Apretude, CAB LA for PrEP
ViiV Healthcare, GlaxoSmithKline, PPD
HIV Infections
06/27
06/27
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
07/24
07/24
NCT04311502: Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Completed
2
104
RoW
Clofazimine (CFZ), Rifapentine (RPT), Isoniazid (INH), Pyrazinamide (PZA), Ethambutol (EMB), Rifampicin (RIF), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
06/24
06/24
Marimbe-Mukwekwerere, Pamela
NCT05383742: Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Recruiting
2
330
RoW
Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD), Pyrazinamide (PZA), ethambutol (EMB), Rifampicin, Isoniazid
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis
05/27
05/27

Download Options